A multivalent or polyvalent vaccine is designed to immunize against two or more strains of the same microorganism, or against two or more microorganisms. The term “multivalent/polyvalent vaccine” is commonly used to depict either an immunization with the capacity to shield against more than one illness or a vaccine that protects against multiple strains of a solitary pathogen.
Drivers & Restraints
The growth of this market is majorly attributed to the high prevalence of infectious diseases, increasing company initiatives to enhance vaccine Research & Development, growing government support for vaccine development, and the rising focus on immunization. However, the huge capital investments required for developing vaccines may restrain market growth.
Sample Link Here: https://www.asamarketresearch.com/request-sample/998285
Inactivated and Subunit Vaccines
Live Attenuated Vaccines
The market has been segment into North America, South America, Europe, Asia-Pacific, and Middle East and Africa. North America accounted for the largest share of the vaccines market in 2018.
Purchase Link Here: https://www.asamarketresearch.com/checkout/998285
- GlaxoSmithKline, plc
- Pfizer, Inc.
- Merck & Co., Inc.
- Sanofi Pasteur SA
- Astellas Pharma Inc.
- CSL Limited
- Emergent BioSolutions, Inc.
- Johnson & Johnson
- Serum Institute of India Pvt. Ltd.
- Mitsubishi Tanabe Pharma Corporation
- Daiichi Sankyo
- Panacea Biotec